How effective is Ixazomib?

Ixazomib is a cancer drug used to treat multiple myeloma, a cancer of the bone marrow, in adults. It is used with two other drugs, lenalidomide and dexamethasone, in patients who have received at least one prior treatment. Due to the small number of patients with multiple myeloma, the disease is considered a "rare disease", and Ixazomib(Ixazomib) /span>2011Year9Month27 was designated as an “orphan drug” (a drug for rare diseases).

Ixazomib was investigated in a major study involving 722 adults with multiple myeloma whose disease did not improve or relapsed after prior treatment. The study comparedixazomibwith placebo (a dummy treatment), both taken with lenalidomide and dexamethasone. The first analysis of the data showed that ixazomib was effective in extending the time patients lived without disease progression (progression-free survival). Patients who received ixazomib lived an average of 21 months, while those who received placebo lived an average of 15 months. However, there is uncertainty about the extent of the improvement, as further analysis of the data showed a reduced effect.

In a subsequent similar study involving 115 patients, many of whom had advanced disease, those who received ixazomib and lenalidomide and dexamethasone lived an average of 6.7 months without disease progression, while those who received placebo and lenalidomide and dexamethasone lived an average of 4 months. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.